A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

NCT00630370 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Post Prandial Distress Syndrome

Interventions

DRUG: Placebo
DRUG: 20 mg ATI 7505
DRUG: 40 mg ATI 7505
DRUG: 80 mg ATI 7505

Sponsor

Procter and Gamble

Collaborators

[object Object]